NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
TuHURA Biosciences, Inc./NV HURA
16 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
EPS · FY25
$-0.63
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-169.2%
Net margin · FY25
—
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
—
Revenue, FY2025 · full 16-year series below
Revenue
Net income
Per share
USD -0.63
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-169.2%
Return on equity, FY2025
ROE
Operating margin—
Net margin—
Return on assets-127.0%
Each USD of equity lost 169 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.06B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 27.4M
total assets, end of FY2025
Total assetsUSD 27.4M
EquityUSD 20.9M
CashUSD 3.6M
Current ratio0.78×
Equity funds 77% of total assets.
History
16 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
Revenue $B
0.0
0.0
0.0
·
·
·
·
·
·
·
·
·
·
·
0.0
0.0
Operating income $B
−0.0
−0.0
0.0
·
·
·
·
·
·
·
·
·
·
·
−0.0
−0.0
EBITDA $B
−0.0
−0.0
0.0
·
·
·
·
·
·
·
·
·
·
·
·
·
Income tax $B
0.0
0.0
0.0
·
·
·
·
·
·
·
·
·
·
·
·
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
0.0
0.0
−0.0
0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.63
−1.21
−2.47
·
·
·
·
·
·
·
·
−0.11
0.00
−0.18
−0.16
0.00
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−169.2
−332.7
·
−233.9
−202.5
−706.3
−818.1
−217.4
185.4
141.3
439.1
·
·
·
·
−121.4
Shares out B
0.06
0.01
0.01
·
·
·
·
0.00
0.00
0.00
0.00
0.00
0.04
0.01
0.00
0.01
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
45 of 45
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed